You just read:

Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia

News provided by

Convergence Pharmaceuticals

23 Apr, 2013, 12:32 BST